{
    "hands_on_practices": [
        {
            "introduction": "In drug discovery, a key objective is to determine a drug's binding affinity for its target. While competitive binding assays yield a half-maximal inhibitory concentration ($IC_{50}$), this value is dependent on the specific experimental conditions. This practice demonstrates how to use the Cheng-Prusoff equation to convert the context-dependent $IC_{50}$ into the intrinsic inhibition constant ($K_i$), a true measure of a drug's affinity that allows for valid comparisons across different studies and compounds .",
            "id": "4956221",
            "problem": "A competitive binding assay is performed at the human histamine $H_1$ receptor using histamine as the labeled ligand. Under these equilibrium assay conditions, the histamine equilibrium dissociation constant (denoted $K_d$) is measured to be $5\\,\\mathrm{nM}$. At a fixed labeled histamine concentration $[L] = 10\\,\\mathrm{nM}$, a candidate histamine $H_1$ receptor antagonist yields a half-maximal inhibitory concentration ($IC_{50}$) of $20\\,\\mathrm{nM}$ for displacement of the labeled histamine from receptors.\n\nStarting from the law of mass action and the core definitions of the equilibrium dissociation constant ($K_d$) and the inhibition constant ($K_i$), derive the general relationship between the observed $IC_{50}$ and the true $K_i$ for a competitive antagonist at a single binding site in the presence of a fixed labeled ligand concentration $[L]$. Then use your derived relationship to compute the antagonist’s $K_i$ for the histamine $H_1$ receptor under the given conditions.\n\nExpress the final $K_i$ in $\\mathrm{nM}$ and round your numerical answer to four significant figures. After computing the number, briefly interpret the result in terms of the antagonist’s affinity and why the observed $IC_{50}$ differs from $K_i$ when $[L]$ is not negligible compared to $K_d$.",
            "solution": "The problem is well-posed and scientifically grounded in the principles of receptor pharmacology and chemical kinetics. We can proceed with the derivation and calculation.\n\nThe first step is to derive the general relationship between the half-maximal inhibitory concentration ($IC_{50}$) and the inhibitor's equilibrium dissociation constant ($K_i$) for a competitive antagonist. This relationship is commonly known as the Cheng-Prusoff equation.\n\nLet $R$ be the receptor, $L$ be the labeled ligand (histamine), and $I$ be the competitive inhibitor (antagonist). At equilibrium, we have three species of receptor: free receptor $[R]$, receptor bound to ligand $[RL]$, and receptor bound to inhibitor $[RI]$. The total receptor concentration, $[R_T]$, is the sum of these species:\n$$[R_T] = [R] + [RL] + [RI]$$\nThe interactions are governed by the law of mass action, leading to the definitions of the equilibrium dissociation constants for the ligand ($K_d$) and the inhibitor ($K_i$):\n$$K_d = \\frac{[R][L]}{[RL]}$$\n$$K_i = \\frac{[R][I]}{[RI]}$$\nFrom these definitions, we can express $[RL]$ and $[RI]$ in terms of the free receptor concentration $[R]$:\n$$[RL] = \\frac{[R][L]}{K_d}$$\n$$[RI] = \\frac{[R][I]}{K_i}$$\nSubstituting these expressions into the equation for total receptor concentration:\n$$[R_T] = [R] + \\frac{[R][L]}{K_d} + \\frac{[R][I]}{K_i} = [R] \\left( 1 + \\frac{[L]}{K_d} + \\frac{[I]}{K_i} \\right)$$\nThe amount of bound ligand, $[RL]$, can be expressed as a function of total receptors $[R_T]$ by first expressing $[R]$ in terms of $[R_T]$:\n$$[R] = \\frac{[R_T]}{1 + \\frac{[L]}{K_d} + \\frac{[I]}{K_i}}$$\nAnd then substituting this into the expression for $[RL]$:\n$$[RL] = \\frac{1}{K_d} [L] [R] = \\frac{\\frac{[L]}{K_d} [R_T]}{1 + \\frac{[L]}{K_d} + \\frac{[I]}{K_i}}$$\nThe $IC_{50}$ is defined as the concentration of inhibitor ($[I]$) that reduces the specific binding of the labeled ligand by $50\\%$. The specific binding of the ligand is proportional to $[RL]$. We first find the binding in the absence of inhibitor, $[RL]_0$, by setting $[I]=0$:\n$$[RL]_0 = \\frac{\\frac{[L]}{K_d} [R_T]}{1 + \\frac{[L]}{K_d}}$$\nBy definition, at $[I] = IC_{50}$, the concentration of bound ligand, $[RL]_{IC_{50}}$, is half of the concentration in the absence of inhibitor:\n$$[RL]_{IC_{50}} = \\frac{1}{2} [RL]_0$$\nSubstituting the expressions for $[RL]$:\n$$\\frac{\\frac{[L]}{K_d} [R_T]}{1 + \\frac{[L]}{K_d} + \\frac{IC_{50}}{K_i}} = \\frac{1}{2} \\left( \\frac{\\frac{[L]}{K_d} [R_T]}{1 + \\frac{[L]}{K_d}} \\right)$$\nWe can cancel the common term $\\frac{[L]}{K_d} [R_T]$ from both sides, provided it is non-zero (which it is, as $[L]>0$ and $[R_T]>0$):\n$$\\frac{1}{1 + \\frac{[L]}{K_d} + \\frac{IC_{50}}{K_i}} = \\frac{1}{2 \\left( 1 + \\frac{[L]}{K_d} \\right)}$$\nTaking the reciprocal of both sides gives:\n$$1 + \\frac{[L]}{K_d} + \\frac{IC_{50}}{K_i} = 2 \\left( 1 + \\frac{[L]}{K_d} \\right)$$\n$$1 + \\frac{[L]}{K_d} + \\frac{IC_{50}}{K_i} = 2 + 2\\frac{[L]}{K_d}$$\nRearranging the terms to solve for the term containing $IC_{50}$:\n$$\\frac{IC_{50}}{K_i} = \\left( 2 + 2\\frac{[L]}{K_d} \\right) - \\left( 1 + \\frac{[L]}{K_d} \\right) = 1 + \\frac{[L]}{K_d}$$\nThis gives the general relationship between $IC_{50}$ and $K_i$:\n$$IC_{50} = K_i \\left( 1 + \\frac{[L]}{K_d} \\right)$$\nTo compute the antagonist's $K_i$, we rearrange this equation:\n$$K_i = \\frac{IC_{50}}{1 + \\frac{[L]}{K_d}}$$\nNow we use the given values from the problem statement:\n- Labeled ligand (histamine) concentration, $[L] = 10 \\, \\mathrm{nM}$\n- Histamine equilibrium dissociation constant, $K_d = 5 \\, \\mathrm{nM}$\n- Antagonist half-maximal inhibitory concentration, $IC_{50} = 20 \\, \\mathrm{nM}$\n\nSubstituting these values into the derived equation:\n$$K_i = \\frac{20 \\, \\mathrm{nM}}{1 + \\frac{10 \\, \\mathrm{nM}}{5 \\, \\mathrm{nM}}}$$\n$$K_i = \\frac{20}{1 + 2}$$\n$$K_i = \\frac{20}{3} \\, \\mathrm{nM}$$\nThe problem asks for the numerical answer rounded to four significant figures.\n$$K_i \\approx 6.6666... \\, \\mathrm{nM}$$\n$$K_i \\approx 6.667 \\, \\mathrm{nM}$$\n\nFinally, we interpret this result. The calculated value $K_i = 6.667 \\, \\mathrm{nM}$ represents the antagonist's equilibrium dissociation constant at the histamine $H_1$ receptor. The $K_i$ is an intrinsic measure of the antagonist's binding affinity; a lower $K_i$ value corresponds to a higher affinity. This value is independent of the labeled ligand concentration used in the assay.\n\nThe observed $IC_{50}$ of $20 \\, \\mathrm{nM}$ is greater than the true $K_i$ of $6.667 \\, \\mathrm{nM}$ because the assay was performed with a concentration of labeled ligand ($[L] = 10 \\, \\mathrm{nM}$) that is not negligible compared to its own dissociation constant ($K_d = 5 \\, \\mathrm{nM}$). In fact, $[L]$ is twice $K_d$. The presence of the labeled ligand creates a competitive environment for the antagonist. To displace $50\\%$ of the bound labeled ligand, the antagonist must not only overcome its own dissociation tendency (quantified by $K_i$) but also successfully compete against the binding of the labeled ligand. This additional competitive burden increases the concentration of antagonist required to achieve $50\\%$ inhibition, causing the observed $IC_{50}$ to be higher than the intrinsic $K_i$. The extent of this increase is given by the factor $\\left(1 + \\frac{[L]}{K_d}\\right)$, which in this case is $\\left(1 + \\frac{10}{5}\\right) = 3$. Thus, the measured $IC_{50}$ is exactly three times the true $K_i$. If the labeled ligand concentration were negligibly small ($[L] \\ll K_d$), the observed $IC_{50}$ would be approximately equal to the $K_i$.",
            "answer": "$$ \\boxed{6.667} $$"
        },
        {
            "introduction": "An ideal drug would interact exclusively with its intended target, but in reality, many drugs bind to multiple receptors, leading to off-target effects. Building on the concept of affinity ($K_i$), this exercise explores how to quantify a drug's receptor selectivity by comparing its affinity for the target H₁ receptor against other histamine receptor subtypes. By calculating selectivity ratios and estimating receptor occupancy at a therapeutic concentration, you will learn to make quantitative predictions about a drug's potential for side effects .",
            "id": "4956281",
            "problem": "A competitive histamine receptor antagonist is characterized by radioligand displacement binding studies, yielding inhibition constants $\\;K_{i}\\;$ against the four histamine receptor subtypes: H1, H2, H3, and H4. The measured values are $K_i(\\mathrm{H1})=2\\,\\mathrm{nM}$, $K_i(\\mathrm{H2})=500\\,\\mathrm{nM}$, $K_i(\\mathrm{H3})=3\\,\\mu\\mathrm{M}$, and $K_i(\\mathrm{H4})=1\\,\\mu\\mathrm{M}$. Assume the drug acts at the orthosteric binding site and that the inhibition constant $K_{i}$ approximates the equilibrium dissociation constant $K_{d}$ for receptor binding in the relevant physiological context. At a therapeutic free plasma drug concentration of $10\\,\\mathrm{nM}$, receptors are at equilibrium with the ligand, and receptor concentrations are negligible relative to the free ligand concentration.\n\nUsing the law of mass action and the equilibrium definition of binding affinity, reason from first principles to:\n\n1. Define and compute the selectivity ratios of H1 over each other histamine receptor subtype as $S_{\\mathrm{H1}/\\mathrm{Hx}}=\\dfrac{K_{i}(\\mathrm{Hx})}{K_{i}(\\mathrm{H1})}$ for $\\mathrm{Hx}\\in\\{\\mathrm{H2},\\mathrm{H3},\\mathrm{H4}\\}$.\n2. Based on receptor occupancy reasoning grounded in equilibrium binding, interpret whether off-target effects mediated by H2, H3, or H4 are plausible at $10\\,\\mathrm{nM}$ free drug.\n\nAnswer specification: Report only the three selectivity ratios $S_{\\mathrm{H1}/\\mathrm{H2}}$, $S_{\\mathrm{H1}/\\mathrm{H3}}$, and $S_{\\mathrm{H1}/\\mathrm{H4}}$ in the final answer, expressed as dimensionless numbers. Round each value to three significant figures. Express the final answer as a row matrix.",
            "solution": "The problem statement is evaluated and found to be valid. It is scientifically grounded in the principles of receptor pharmacology, well-posed with all necessary information provided, and objective in its language. The data are consistent and realistic for a selective drug, and the assumptions are clearly stated and standard for this type of analysis.\n\nThe solution proceeds in two parts as requested. First, we compute the selectivity ratios. Second, we interpret the potential for off-target effects based on receptor occupancy theory.\n\nPart 1: Calculation of Selectivity Ratios\n\nThe selectivity of a ligand for a target receptor (here, $\\mathrm{H1}$) over an off-target receptor (here, $\\mathrm{Hx}$) is a measure of the difference in binding affinity. The inhibition constant, $K_i$, is a measure of affinity, where a smaller $K_i$ value corresponds to a higher affinity. The problem defines the selectivity ratio as:\n$$\nS_{\\mathrm{H1}/\\mathrm{Hx}} = \\frac{K_{i}(\\mathrm{Hx})}{K_{i}(\\mathrm{H1})}\n$$\nA large value of $S_{\\mathrm{H1}/\\mathrm{Hx}}$ indicates that the drug binds to the target receptor $\\mathrm{H1}$ with much higher affinity than it binds to the off-target receptor $\\mathrm{Hx}$, implying high selectivity for $\\mathrm{H1}$.\n\nThe given inhibition constants are:\n$K_{i}(\\mathrm{H1}) = 2\\,\\mathrm{nM}$\n$K_{i}(\\mathrm{H2}) = 500\\,\\mathrm{nM}$\n$K_{i}(\\mathrm{H3}) = 3\\,\\mu\\mathrm{M}$\n$K_{i}(\\mathrm{H4}) = 1\\,\\mu\\mathrm{M}$\n\nTo compute the dimensionless selectivity ratios, all constants must be in the same units. We convert all values to nanomolars ($\\mathrm{nM}$). Since $1\\,\\mu\\mathrm{M} = 1000\\,\\mathrm{nM}$:\n$K_{i}(\\mathrm{H3}) = 3\\,\\mu\\mathrm{M} = 3 \\times 10^3\\,\\mathrm{nM}$\n$K_{i}(\\mathrm{H4}) = 1\\,\\mu\\mathrm{M} = 1 \\times 10^3\\,\\mathrm{nM}$\n\nNow we compute the three selectivity ratios:\n\n1.  Selectivity for $\\mathrm{H1}$ over $\\mathrm{H2}$:\n    $$\n    S_{\\mathrm{H1}/\\mathrm{H2}} = \\frac{K_{i}(\\mathrm{H2})}{K_{i}(\\mathrm{H1})} = \\frac{500\\,\\mathrm{nM}}{2\\,\\mathrm{nM}} = 250\n    $$\n\n2.  Selectivity for $\\mathrm{H1}$ over $\\mathrm{H3}$:\n    $$\n    S_{\\mathrm{H1}/\\mathrm{H3}} = \\frac{K_{i}(\\mathrm{H3})}{K_{i}(\\mathrm{H1})} = \\frac{3 \\times 10^3\\,\\mathrm{nM}}{2\\,\\mathrm{nM}} = 1500\n    $$\n\n3.  Selectivity for $\\mathrm{H1}$ over $\\mathrm{H4}$:\n    $$\n    S_{\\mathrm{H1}/\\mathrm{H4}} = \\frac{K_{i}(\\mathrm{H4})}{K_{i}(\\mathrm{H1})} = \\frac{1 \\times 10^3\\,\\mathrm{nM}}{2\\,\\mathrm{nM}} = 500\n    $$\n\nThese values indicate the drug is $250$-fold selective for $\\mathrm{H1}$ over $\\mathrm{H2}$, $1500$-fold selective for $\\mathrm{H1}$ over $\\mathrm{H3}$, and $500$-fold selective for $\\mathrm{H1}$ over $\\mathrm{H4}$.\n\nPart 2: Interpretation of Off-Target Effects\n\nTo assess the plausibility of off-target effects, we must determine the fractional occupancy of each receptor subtype at the given therapeutic free drug concentration, $[L] = 10\\,\\mathrm{nM}$.\n\nFrom the law of mass action for a ligand $L$ binding to a receptor $R$, the fractional receptor occupancy, $\\theta$, is given by the Hill-Langmuir equation:\n$$\n\\theta = \\frac{[L]}{[L] + K_d}\n$$\nThe problem states the assumption that the inhibition constant $K_i$ approximates the equilibrium dissociation constant $K_d$ ($K_i \\approx K_d$). We can therefore use the given $K_i$ values to calculate the occupancy for each receptor subtype.\n\n-   Occupancy of the target receptor, $\\mathrm{H1}$:\n    $$\n    \\theta_{\\mathrm{H1}} = \\frac{[L]}{[L] + K_{i}(\\mathrm{H1})} = \\frac{10\\,\\mathrm{nM}}{10\\,\\mathrm{nM} + 2\\,\\mathrm{nM}} = \\frac{10}{12} = \\frac{5}{6} \\approx 0.833\n    $$\n    At the therapeutic concentration, approximately $83.3\\%$ of $\\mathrm{H1}$ receptors are occupied, which is a substantial level of occupancy consistent with producing a therapeutic effect.\n\n-   Occupancy of the off-target receptor, $\\mathrm{H2}$:\n    $$\n    \\theta_{\\mathrm{H2}} = \\frac{[L]}{[L] + K_{i}(\\mathrm{H2})} = \\frac{10\\,\\mathrm{nM}}{10\\,\\mathrm{nM} + 500\\,\\mathrm{nM}} = \\frac{10}{510} = \\frac{1}{51} \\approx 0.0196\n    $$\n    The occupancy of $\\mathrm{H2}$ receptors is approximately $2.0\\%$.\n\n-   Occupancy of the off-target receptor, $\\mathrm{H3}$:\n    $$\n    \\theta_{\\mathrm{H3}} = \\frac{[L]}{[L] + K_{i}(\\mathrm{H3})} = \\frac{10\\,\\mathrm{nM}}{10\\,\\mathrm{nM} + 3000\\,\\mathrm{nM}} = \\frac{10}{3010} = \\frac{1}{301} \\approx 0.00332\n    $$\n    The occupancy of $\\mathrm{H3}$ receptors is approximately $0.33\\%$.\n\n-   Occupancy of the off-target receptor, $\\mathrm{H4}$:\n    $$\n    \\theta_{\\mathrm{H4}} = \\frac{[L]}{[L] + K_{i}(\\mathrm{H4})} = \\frac{10\\,\\mathrm{nM}}{10\\,\\mathrm{nM} + 1000\\,\\mathrm{nM}} = \\frac{10}{1010} = \\frac{1}{101} \\approx 0.00990\n    $$\n    The occupancy of $\\mathrm{H4}$ receptors is approximately $1.0\\%$.\n\nInterpretation: The occupancies for the off-target receptors $\\mathrm{H2}$, $\\mathrm{H3}$, and $\\mathrm{H4}$ are all extremely low (all are $\\le 2\\%$). In general pharmacology, significant physiological or adverse effects are not typically observed at such low levels of receptor occupancy. While there is no universal threshold, occupancies below $10\\%$ are commonly considered unlikely to be physiologically relevant. Therefore, based on this equilibrium binding analysis, off-target effects mediated by $\\mathrm{H2}$, $\\mathrm{H3}$, or $\\mathrm{H4}$ receptors at a free drug concentration of $10\\,\\mathrm{nM}$ are deemed implausible. The drug displays high functional selectivity for its target, $\\mathrm{H1}$, at its therapeutic concentration.\n\nThe final answer requires the three selectivity ratios, rounded to three significant figures.\n$S_{\\mathrm{H1}/\\mathrm{H2}} = 250 \\rightarrow 2.50 \\times 10^2$\n$S_{\\mathrm{H1}/\\mathrm{H3}} = 1500 \\rightarrow 1.50 \\times 10^3$\n$S_{\\mathrm{H1}/\\mathrm{H4}} = 500 \\rightarrow 5.00 \\times 10^2$",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n2.50 \\times 10^{2} & 1.50 \\times 10^{3} & 5.00 \\times 10^{2}\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Beyond its affinity and selectivity, a drug's clinical utility is critically dependent on its pharmacokinetic properties—how it is absorbed, distributed, metabolized, and eliminated. This practice shifts the focus from pharmacodynamics to pharmacokinetics to explore how an H₁ antihistamine behaves in the body over time with repeated dosing. By analyzing the relationship between a drug's elimination half-life ($t_{1/2}$) and dosing interval ($\\tau$), you will determine how the drug accumulates and how long it takes to reach a stable, therapeutic concentration in the body .",
            "id": "4956286",
            "problem": "A second-generation histamine $\\mathrm{H}_1$ receptor antagonist (an $\\mathrm{H}_1$ antihistamine) is administered orally as the same dose once every $\\tau = 24 \\ \\mathrm{h}$ to a patient. Assume linear one-compartment pharmacokinetics with first-order elimination and negligible absorption lag so that the post-dose peak concentration occurs immediately after each dose. The drug’s terminal elimination half-life is $t_{1/2} = 14 \\ \\mathrm{h}$. \n\nStarting from fundamental definitions of first-order elimination and superposition for repeated dosing, and without assuming any pre-memorized shortcut formulas, determine:\n1. The steady-state accumulation ratio of post-dose peak concentrations, defined as the ratio of the steady-state peak concentration immediately after a dose to the peak concentration immediately after the very first dose.\n2. The earliest time after therapy initiation when the post-dose peak concentration first reaches $0.95$ of its steady-state peak value. Interpret “earliest time” with respect to the sequence of immediate post-dose peaks at dosing times.\n\nExpress the accumulation ratio as a pure number and the time in hours. Round both quantities to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in standard pharmacokinetic principles, is well-posed with sufficient and consistent information, and is expressed in objective, formal language. We can proceed with the solution.\n\nThe pharmacokinetics of the drug are described by a linear one-compartment model with first-order elimination. The concentration $C(t)$ of the drug at time $t$ after a single dose that produces an initial peak concentration $C_0$ is given by:\n$$C(t) = C_0 \\exp(-k_{el} t)$$\nwhere $k_{el}$ is the first-order elimination rate constant.\n\nThe rate constant $k_{el}$ is related to the drug's elimination half-life, $t_{1/2}$. By definition, at $t = t_{1/2}$, the concentration is reduced by half, i.e., $C(t_{1/2}) = C_0/2$.\n$$\\frac{C_0}{2} = C_0 \\exp(-k_{el} t_{1/2})$$\n$$\\frac{1}{2} = \\exp(-k_{el} t_{1/2})$$\nTaking the natural logarithm of both sides gives:\n$$\\ln\\left(\\frac{1}{2}\\right) = -k_{el} t_{1/2}$$\n$$-\\ln(2) = -k_{el} t_{1/2}$$\n$$k_{el} = \\frac{\\ln(2)}{t_{1/2}}$$\nGiven $t_{1/2} = 14 \\ \\mathrm{h}$, the elimination rate constant is:\n$$k_{el} = \\frac{\\ln(2)}{14} \\ \\mathrm{h}^{-1}$$\nThe drug is administered at a constant dosing interval of $\\tau = 24 \\ \\mathrm{h}$. The assumption of negligible absorption lag means that the peak concentration occurs immediately after administration, analogous to an intravenous bolus injection.\n\nLet $C_{peak,n}$ be the peak concentration immediately after the $n^{th}$ dose. Let the increase in concentration resulting from a single dose be $C_{peak,1}$. We can use this as a reference, setting $C_{peak,1} = C_{0}$.\n\nThe peak concentration after the first dose (at time $t=0$) is $C_{peak,1} = C_0$.\nThe concentration remaining just before the second dose (at time $t=\\tau$) is $C_0 \\exp(-k_{el} \\tau)$.\nThe peak concentration after the second dose (at time $t=\\tau$) is the sum of the remaining concentration and the concentration increase from the new dose:\n$$C_{peak,2} = C_0 \\exp(-k_{el} \\tau) + C_0 = C_0 (1 + \\exp(-k_{el} \\tau))$$\nSimilarly, the peak concentration after the third dose (at time $t=2\\tau$) is:\n$$C_{peak,3} = C_{peak,2} \\exp(-k_{el} \\tau) + C_0 = C_0 (1 + \\exp(-k_{el} \\tau)) \\exp(-k_{el} \\tau) + C_0 = C_0 (\\exp(-k_{el} \\tau) + \\exp(-2k_{el} \\tau)) + C_0 = C_0 (1 + \\exp(-k_{el} \\tau) + \\exp(-2k_{el} \\tau))$$\nFollowing this pattern, the peak concentration after the $n^{th}$ dose is the sum of contributions from all $n$ doses:\n$$C_{peak,n} = \\sum_{i=0}^{n-1} C_0 \\exp(-i k_{el} \\tau) = C_0 \\sum_{i=0}^{n-1} (\\exp(-k_{el} \\tau))^i$$\nThis is a finite geometric series with the first term $a=1$, common ratio $r = \\exp(-k_{el} \\tau)$, and $n$ terms. The sum is given by $S_n = a \\frac{1-r^n}{1-r}$.\n$$C_{peak,n} = C_0 \\frac{1 - (\\exp(-k_{el} \\tau))^n}{1 - \\exp(-k_{el} \\tau)} = C_0 \\frac{1 - \\exp(-n k_{el} \\tau)}{1 - \\exp(-k_{el} \\tau)}$$\n\n**1. Steady-State Accumulation Ratio ($R_{acc}$)**\n\nSteady state is achieved as the number of doses $n$ approaches infinity ($n \\to \\infty$). Since $k_{el} > 0$ and $\\tau > 0$, the ratio $|\\exp(-k_{el} \\tau)| < 1$. Therefore, as $n \\to \\infty$, the term $\\exp(-n k_{el} \\tau)$ approaches $0$. The steady-state peak concentration, $C_{peak,ss}$, is:\n$$C_{peak,ss} = \\lim_{n \\to \\infty} C_{peak,n} = C_0 \\frac{1 - 0}{1 - \\exp(-k_{el} \\tau)} = \\frac{C_0}{1 - \\exp(-k_{el} \\tau)}$$\nThe accumulation ratio, $R_{acc}$, is defined as the ratio of the steady-state peak concentration to the peak concentration after the first dose:\n$$R_{acc} = \\frac{C_{peak,ss}}{C_{peak,1}} = \\frac{\\frac{C_0}{1 - \\exp(-k_{el} \\tau)}}{C_0} = \\frac{1}{1 - \\exp(-k_{el} \\tau)}$$\nTo calculate the numerical value, we first compute the product $k_{el} \\tau$:\n$$k_{el} \\tau = \\frac{\\ln(2)}{14 \\ \\mathrm{h}} \\times 24 \\ \\mathrm{h} = \\frac{12 \\ln(2)}{7}$$\nNow, substitute this into the expression for $R_{acc}$:\n$$R_{acc} = \\frac{1}{1 - \\exp\\left(-\\frac{12 \\ln(2)}{7}\\right)} = \\frac{1}{1 - (\\exp(\\ln(2)))^{-12/7}} = \\frac{1}{1 - 2^{-12/7}}$$\nNumerically, this is:\n$$R_{acc} \\approx \\frac{1}{1 - 2^{-1.71428...}} \\approx \\frac{1}{1 - 0.30475...} \\approx 1.438345...$$\nRounding to four significant figures, the accumulation ratio is $1.438$.\n\n**2. Time to Reach $0.95$ of Steady-State Peak**\n\nWe need to find the earliest time when the post-dose peak concentration first reaches or exceeds $0.95$ of its steady-state value. This corresponds to finding the smallest integer $n$ (dose number) that satisfies the inequality:\n$$C_{peak,n} \\ge 0.95 \\times C_{peak,ss}$$\nSubstituting the derived expressions for $C_{peak,n}$ and $C_{peak,ss}$:\n$$C_0 \\frac{1 - \\exp(-n k_{el} \\tau)}{1 - \\exp(-k_{el} \\tau)} \\ge 0.95 \\left( \\frac{C_0}{1 - \\exp(-k_{el} \\tau)} \\right)$$\nDividing both sides by the common positive term $\\frac{C_0}{1 - \\exp(-k_{el} \\tau)}$ simplifies the inequality to:\n$$1 - \\exp(-n k_{el} \\tau) \\ge 0.95$$\n$$0.05 \\ge \\exp(-n k_{el} \\tau)$$\nTaking the natural logarithm of both sides:\n$$\\ln(0.05) \\ge -n k_{el} \\tau$$\nMultiplying by $-1$ reverses the inequality sign:\n$$-\\ln(0.05) \\le n k_{el} \\tau$$\nUsing the property $-\\ln(x) = \\ln(1/x)$:\n$$\\ln\\left(\\frac{1}{0.05}\\right) \\le n k_{el} \\tau$$\n$$\\ln(20) \\le n k_{el} \\tau$$\nNow, we solve for $n$:\n$$n \\ge \\frac{\\ln(20)}{k_{el} \\tau}$$\nSubstituting the value of $k_{el}\\tau = \\frac{12 \\ln(2)}{7}$:\n$$n \\ge \\frac{\\ln(20)}{\\frac{12 \\ln(2)}{7}} = \\frac{7 \\ln(20)}{12 \\ln(2)}$$\nCalculating the numerical value for this lower bound:\n$$n \\ge \\frac{7 \\times 2.99573...}{12 \\times 0.693147...} \\approx \\frac{20.9701...}{8.31776...} \\approx 2.5211...$$\nSince $n$ must be an integer (representing the dose number), the smallest integer value for $n$ that satisfies this condition is $n=3$.\nThis means the condition is first met immediately after the $3^{rd}$ dose. The problem asks for the earliest time, which is the time of administration of this dose. The $n^{th}$ dose is administered at time $t = (n-1)\\tau$.\nFor $n=3$, the time is:\n$$t = (3 - 1)\\tau = 2\\tau$$\nSubstituting $\\tau = 24 \\ \\mathrm{h}$:\n$$t = 2 \\times 24 \\ \\mathrm{h} = 48 \\ \\mathrm{h}$$\nRounding to four significant figures, the time is $48.00 \\ \\mathrm{h}$.\n\nThe final answers are an accumulation ratio of $1.438$ and a time of $48.00 \\ \\mathrm{h}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1.438 & 48.00\n\\end{pmatrix}\n}\n$$"
        }
    ]
}